LAX.SH
ORCHID PHARMA LIMITED·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
1,002.05
+2.24%52W Range
Market Cap
₹5,082.31 Cr
Traded: ₹10.64 Cr (0.21%) 0.0x
Free Float: ₹438.09 Cr (2.43% of FF traded)
Volume · 60D trend
1.06 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | +5.0% | +6.0% | -- | -- | Accelerating |
| Return | +40.0% | +20.0% | +25.0% | +40.0% | -- | Accelerating |
| Profit | +8.0% | +17.0% | +40.0% | -- | -72.0% | Stable |
| Sales | +4.0% | +22.0% | +23.0% | -- | +14.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 304 | 368 | 207 | 194 | 263 | 237 | 217 | 223 | 244 | 217 | 221 | 199 | 183 | 210 | 160 | 165 |
| Expenses | 290 | 338 | 206 | 195 | 269 | 209 | 191 | 192 | 212 | 188 | 185 | 175 | 161 | 170 | 146 | 147 |
| Operating Profit | 14 | 30 | 2 | -1 | -6 | 28 | 26 | 30 | 32 | 29 | 35 | 23 | 22 | 40 | 14 | 18 |
| OPM % | 4.6% | 8.2% | 0.8% | -0.8% | -2.1% | 11.8% | 12.1% | 13.6% | 13.3% | 13.3% | 16.0% | 11.7% | 12.1% | 19.0% | 9.0% | 10.8% |
| Other Income | 2 | 8 | -2 | 11 | 12 | 4 | 8 | 8 | 8 | 13 | 8 | 8 | 2 | 34 | 9 | 6 |
| Interest | 2 | 2 | 3 | 4 | 2 | 4 | 4 | 3 | 4 | 3 | 4 | 4 | 6 | 7 | 8 | 9 |
| Depreciation | 11 | 11 | 9 | 9 | 11 | 9 | 9 | 9 | 8 | 8 | 9 | 8 | 8 | 7 | 8 | 18 |
| Profit Before Tax | 3 | 25 | -12 | -3 | -7 | 19 | 22 | 26 | 28 | 30 | 30 | 20 | 11 | 59 | 7 | -3 |
| Tax % | 2.6% | 0.0% | 0.0% | 0.0% | 0.0% | -0.2% | 0.0% | 0.0% | -0.5% | -10.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Profit | 3 | 26 | -13 | -6 | -6 | 22 | 21 | 27 | 29 | 33 | 29 | 20 | 9 | 59 | 8 | -5 |
| Exceptional Items | 0 | -0 | -7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 0 | 0 |
| EPS (Rs) | 0.6 | 5.1 | -2.5 | -1.1 | -1.1 | 4.4 | 4.1 | 5.4 | 5.8 | 6.5 | 5.8 | 3.9 | 1.9 | 14.5 | 1.9 | -1.3 |
| Sales Growth (YoY) | 15.6% | 55.1% | -4.6% | -13.1% | 7.7% | 9.4% | -1.5% | 12.0% | 33.6% | 3.4% | 37.9% | 20.3% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -17.4% | 77.7% | 7.1% | -26.5% | 10.8% | 9.3% | -2.4% | -8.9% | 12.6% | -1.6% | 11.0% | 8.7% | -12.9% | 31.3% | -3.2% | -- |
| OP Growth (YoY) | 347.8% | 7.8% | -94.1% | -104.8% | -117.4% | -3.2% | -25.5% | 30.2% | 46.7% | -27.7% | 152.7% | 30.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | -53.6% | 1833.3% | 206.1% | 74.0% | -120.2% | 6.1% | -13.1% | -6.6% | 12.4% | -18.3% | 51.8% | 5.2% | -44.6% | 185.7% | -21.4% | -- |
| Profit Growth (YoY) | 157.0% | 17.0% | -126.0% | -121.0% | -119.0% | -32.0% | -29.0% | 38.0% | 212.0% | 23.0% | 288.0% | 467.0% | 163.0% | 671.7% | 172.0% | 68.0% |
| EPS Growth (YoY) | 156.3% | 15.9% | -160.7% | -121.0% | -119.3% | -32.5% | -29.3% | 37.7% | 213.0% | -55.1% | 211.8% | 395.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -87.6% | 304.4% | -120.3% | -0.9% | -125.5% | 7.1% | -23.6% | -7.3% | -10.9% | 12.1% | 48.7% | 110.8% | -87.2% | 679.0% | 240.9% | -- |
| OP Margin | 4.6% | 8.2% | 0.8% | -0.8% | -2.1% | 11.8% | 12.1% | 13.6% | 13.3% | 13.3% | 16.0% | 11.7% | 12.1% | 19.1% | 8.8% | 10.8% |
| Net Margin | 1.1% | 7.0% | -6.1% | -3.0% | -2.2% | 9.4% | 9.6% | 12.2% | 12.0% | 15.2% | 13.3% | 10.0% | 5.1% | 28.1% | 5.0% | -3.3% |
| Material Cost % | 67.0% | 67.0% | 69.0% | 68.0% | 70.0% | 58.0% | 57.0% | 59.0% | 61.0% | 59.0% | 55.0% | 62.0% | 61.0% | 57.0% | 60.0% | 61.0% |
| Employee Cost % | 9.0% | 8.0% | 12.0% | 13.0% | 11.0% | 9.0% | 10.0% | 9.0% | 9.0% | 8.0% | 9.0% | 9.0% | 9.0% | 8.0% | 10.0% | 11.0% |
| P/S | 4.74 | 6.53 | 4.47 | 3.83 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 477.17 | 260.76 | 192.82 | 60.17 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 3.95 | 4.12 | 2.85 | 2.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Audio Recording of the Analyst/Investor Earning Call for Q-1 ended on June 30, 2026
Investors Presentation-Quarter 1 of F.Y.2026-27, ended on June 30, 2026.
Intimation of schedule of Analysts/Investors Earning call for the Quarter-1 ended on June 30, 2026.
Statement of Deviation or variation for the quarter ended June 30, 2026 on the use of proceeds of Funds raised through Qualified Institutional Placement.
Monitoring Agency Report for Quarter-1 of F.Y. 2026-27 ended June 30, 2026.
Revised Audited financial results for the Financial year ended March 31, 2026 pursuant to Scheme of Merger
Financial Results for Quarter-1 of F.Y. 2026-27 ended on June 30, 2026.
Outcome of Board meeting inter alia for considering and approving Unaudited Financial Results for Quarter-1 of F.Y. 2026-27, ended on June 30, 2026.
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Limited reviewed financial ....
Intimation regarding Investor Roadshow
Confirmation certificate under Regulation 74(5) of Securities and Exchange board of India (Depositories and Participants) Regulations, 2018.
Fixation of Record Date pursuant to scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited for alloting shares to Shareholders of Dhanuka Laboratories Limited
Outcome of Board Meeting: Amendment in the Capital Clause of Memorandum of Association of Company pursuant to the effectiveness of Scheme of Amalgamation of Dhanuka Laboratories Limited ....
Outcome of the Board Meeting
Update related to the Scheme of Amalgamation of Dhanuka Laboratories Limited ("Amalgamating Company") with Orchid Pharma Limited ("Amalgamated Company/Company") and their respective Shareholders ....
Announcement under Regulation 30 regarding the licensing and supply agreement with Pharmasyntez JSC, Russia
Intimation of trading window closure for the Quarter-I of Financial Year 2026-27, ending on June 30, 2026
Update for receipt of copy of order related to scheme of Amalgamation of Dhanuka Laboratories limited and Orchid Pharma limited
Disclosure regarding the order passed by Goods and Service Department.
In continuation to our earlier intimation dated March 18, 2026, with respect to merger petition, we would like to inform that Hon''ble National Company Law Tribunal ("NCLT") on June 05, ....
Transcript of Analysts/ Investor Earning Call held on May 26, 2026 for the Quarter and Financial Year ended on March 31, 2026
Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026.
Investor / Analysts call recording for the Quarter- 4 and Financial year ending March 31, 2026.
Investor Presentation for Quarter- IV and Financial year ended on March 31, 2026.
Appointment of Internal Auditor of the Company.
Statement of Deviation or Variation for the Quarter and Financial Year ended on March 31, 2026
Board Meeting Outcome for Outcome of Board Meeting for considering and approving Annual Audited Financial Results for the Quarter and Financial Year ended on March 31, 2026
Board Meeting Outcome for Outcome of Board Meeting for Considering and Approving Annual Audited Financial Results for The Quarter and F.Y. Ended on March 31, 2026.
Intimation of schedule of Analysts/ Investors Earning Call for the Quarter-IV and Financial Year ended on March 31, 2026
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 ,inter alia, to consider and approve Audited Financial Results (Standalone ....
Monitoring Agency Report for the Quarter- IV of financial year 2025-26 ended March 31, 2026.
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015.
Confirmation certificate under Regulation 74(5) of SEBI (Depositories and participants) Regulations, 2018 for the Quarter- IV ended on March 31, 2026 of FY 2025-26.
Intimation of Roadshow scheduled to be held on April 10, 2026.
Update on credit rating of Orchid Pharma Limited
Intimation of Trading Window Closure for Quarter IV for the Financial Year 2025-26, ending on March 31, 2026
Update related to the Scheme of Amalgamation of Dhanuka Laboratories Limited (''Amalgamating Company'') with Orchid Pharma Limited (''Amalgamated Company'') and their respective shareholders ....
Transcript of Analysts/ Investors Earning call held with Public at large on February 12, 2026, through tele-conferencing.
Audio Recording of the Analysts/Investors Earnings Call of Orchid Pharma Limited for the Quarter-3 ended on December 31, 2025.
Monitoring Agency Report for Quarter-III Ended on December 31, 2025
Investor Presentation Quarter III ended on December 31, 2025.
Unaudited limited review Standalone & Consolidated Financial Results for the quarter and year to date ended on December 31, 2025
Unaudited limited reviewed Standalone & Consolidated Financial Results of the Company for the quarter and year to date period ended on December 31, 2025.
Intimation of schedule of Analysts/ Investors Earning Call, ratifying the inadvertent display error in earlier communication, scheduling the meet for the quarter III of financial year 2025-26 ....
Intimation of schedule of Analysts/ Investors Earning Call for the Quarter-III of F.Y. 2025-26 ended on December 31, 2025.
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve Unaudited Limited Reviewed Financial ....
Compliance certificate under regulation 74(5) of SEBI (Depositories and participants) Regulations for the Quarter-III of F.Y. 2025-26 ended on December 31, 2025.
Intimation of Trading Window Closure for the Quarter III of Financial Year 2025-26, ending on December 31, 2025
Transcript of Analysts/ Investors Earning call held with public at large on November 11, 2025 for the quarter ended September 2025
Audio Recording of the Analysts/Earnings call for the Financial Results of the Company for the Q-2 & Half year ended on September 30, 2025.
Annual Reports
13Credit Ratings
6Concalls
24Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Dec 2021
31 Dec 2021Nov 2021
30 Nov 2021Jun 2021
30 Jun 2021Jun 2021
30 Jun 2021Jun 2021
30 Jun 2021Held by ETFs
1 ETFs hold ORCHPHARMA · sorted by weight
Held by Mutual Funds
23 schemes hold ORCHPHARMA · sorted by weight